Richard E Clark
#177,822
Most Influential Person Now
Researcher
Richard E Clark's AcademicInfluence.com Rankings
Richard E Clarkcomputer-science Degrees
Computer Science
#11099
World Rank
#11726
Historical Rank
Computational Linguistics
#2809
World Rank
#2841
Historical Rank
Machine Learning
#5075
World Rank
#5138
Historical Rank
Artificial Intelligence
#5473
World Rank
#5548
Historical Rank
Download Badge
Computer Science
Richard E Clark's Degrees
- PhD Computer Science Stanford University
Similar Degrees You Can Earn
Why Is Richard E Clark Influential?
(Suggest an Edit or Addition)Richard E Clark's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. (2013) (1736)
- Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. (2010) (1224)
- Active transport of imatinib into and out of cells: implications for drug resistance. (2004) (671)
- European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia (2020) (623)
- Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial (2016) (595)
- The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. (2013) (548)
- Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. (2012) (459)
- Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up (2012) (432)
- Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial. (2001) (424)
- A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy. (2004) (405)
- Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial. (2015) (367)
- European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia (2016) (341)
- Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy. (2009) (325)
- Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy: results of a consensus process by an International Working Group. (2007) (325)
- Expression of the Uptake Drug Transporter hOCT1 is an Important Clinical Determinant of the Response to Imatinib in Chronic Myeloid Leukemia (2008) (295)
- Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein. (2001) (261)
- Thrombotic microangiopathy following bone marrow transplantation. (1994) (249)
- A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients. (2014) (226)
- hOCT 1 and resistance to imatinib. (2005) (219)
- Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial. (2016) (195)
- A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia. (2003) (184)
- The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries (2015) (171)
- European development of clofarabine as treatment for older patients with acute myeloid leukemia considered unsuitable for intensive chemotherapy. (2010) (153)
- Cancerous inhibitor of PP2A (CIP2A) at diagnosis of chronic myeloid leukemia is a critical determinant of disease progression. (2011) (148)
- Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia. (2008) (141)
- Imatinib improves but may not fully reverse the poor prognosis of patients with CML with derivative chromosome 9 deletions. (2003) (137)
- Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinib. (2012) (133)
- Loss or inhibition of stromal-derived PlGF prolongs survival of mice with imatinib-resistant Bcr-Abl1(+) leukemia. (2011) (130)
- A Genome-wide screen identifies frequently methylated genes in haematological and epithelial cancers (2010) (108)
- Improving the intracellular delivery and molecular efficacy of antisense oligonucleotides in chronic myeloid leukemia cells: a comparison of streptolysin-O permeabilization, electroporation, and lipophilic conjugation. (1998) (101)
- Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript (2009) (98)
- Serial monitoring of BCR–ABL by peripheral blood real‐time polymerase chain reaction predicts the marrow cytogenetic response to imatinib mesylate in chronic myeloid leukaemia (2002) (98)
- Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis (2021) (96)
- De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial. (2019) (93)
- Antisense morpholino oligonucleotide analog induces missplicing of C-myc mRNA. (1999) (92)
- Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up (2012) (92)
- Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase (2012) (90)
- Diverging effects of HLA–DPB1 matching status on outcome following unrelated donor transplantation depending on disease stage and the degree of matching for other HLA alleles (2010) (87)
- Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies. (2013) (85)
- De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial. (2017) (82)
- Selecting optimal oligonucleotide composition for maximal antisense effect following streptolysin O-mediated delivery into human leukaemia cells. (1998) (76)
- The role of serial BCR-ABL transcript monitoring in predicting the emergence of BCR-ABL kinase mutations in imatinib-treated patients with chronic myeloid leukemia. (2006) (71)
- The hOCT1 SNPs M420del and M408V alter imatinib uptake and M420del modifies clinical outcome in imatinib-treated chronic myeloid leukemia. (2013) (71)
- Targeting BCR-ABL-Independent TKI Resistance in Chronic Myeloid Leukemia by mTOR and Autophagy Inhibition (2017) (70)
- Definitions, methodological and statistical issues for phase 3 clinical trials in chronic myeloid leukemia: a proposal by the European LeukemiaNet. (2012) (67)
- Successful Outcome of Pregnancy in Chronic Myeloid Leukaemia Treated with Imatinib (2004) (58)
- An operational definition of primary refractory acute myeloid leukemia allowing early identification of patients who may benefit from allogeneic stem cell transplantation (2016) (58)
- Epic: A Phase 3 Trial of Ponatinib Compared with Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CP-CML) (2014) (57)
- Simultaneous determination of nilotinib, imatinib and its main metabolite (CGP-74588) in human plasma by ultra-violet high performance liquid chromatography. (2010) (57)
- b3a2 BCR–ABL fusion peptides as targets for cytotoxic T cells in chronic myeloid leukaemia (2000) (56)
- Defining the dose of gemtuzumab ozogamicin in combination with induction chemotherapy in acute myeloid leukemia: a comparison of 3 mg/m2 with 6 mg/m2 in the NCRI AML17 Trial (2016) (56)
- Psychosocial morbidity in bone marrow transplant recipients: a prospective study. (1995) (54)
- Optimization of antisense oligodeoxynucleotide structure for targeting bcr-abl mRNA. (1995) (51)
- Efficacy and Safety of Nilotinib (NIL) vs Imatinib (IM) in Patients (pts) With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Long-Term Follow-Up (f/u) of ENESTnd (2014) (50)
- ENESTnd Update: Nilotinib (NIL) Vs Imatinib (IM) In Patients (pts) With Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP) and The Impact Of Early Molecular Response (EMR) and Sokal Risk At Diagnosis On Long-Term Outcomes (2013) (49)
- ENESTnd Update: Continued Superiority of Nilotinib Versus Imatinib In Patients with Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP) (2010) (49)
- Vosaroxin and vosaroxin plus low-dose Ara-C (LDAC) vs low-dose Ara-C alone in older patients with acute myeloid leukemia. (2015) (49)
- A prospective evaluation of cardiac function in patients with chronic myeloid leukaemia treated with imatinib. (2011) (47)
- Nilotinib is superior to imatinib as first-line therapy of chronic myeloid leukemia: the ENESTnd study (2010) (45)
- Biochemical markers of bone turnover following high-dose chemotherapy and autografting in multiple myeloma. (2000) (44)
- Enestnd 4-Year (y) Update: Continued Superiority of Nilotinib Vs Imatinib in Patients (pts) with Newly Diagnosed Philadelphia Chromosome–Positive (Ph+) Chronic Myeloid Leukemia in Chronic Phase (CML-CP) (2012) (42)
- Circulating bcr-abl-specific CD8+ T cells in chronic myeloid leukemia patients and healthy subjects. (2005) (40)
- Nilotinib Demonstrates Superior Efficacy Compared with Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase: Results From the International Randomized Phase III ENESTnd Trial (2009) (39)
- The influence of target protein half-life on the effectiveness of antisense oligonucleotide analog-mediated biologic responses. (1998) (38)
- A common novel splice variant of SLC22A1 (OCT1) is associated with impaired responses to imatinib in patients with chronic myeloid leukaemia (2013) (37)
- A randomised comparison of the novel nucleoside analogue sapacitabine with low-dose cytarabine in older patients with acute myeloid leukaemia (2015) (36)
- Autografting as a risk factor for persisting iron overload in long-term survivors of acute myeloid leukaemia (2003) (36)
- AC220 (Quizartinib) Can Be Safely Combined With Conventional Chemotherapy In Older Patients With Newly Diagnosed Acute Myeloid Leukaemia: Experience From The AML18 Pilot Trial (2013) (35)
- Axl Blockade by BGB324 Inhibits BCR-ABL Tyrosine Kinase Inhibitor–Sensitive and -Resistant Chronic Myeloid Leukemia (2016) (35)
- CD93 is expressed on chronic myeloid leukemia stem cells and identifies a quiescent population which persists after tyrosine kinase inhibitor therapy (2020) (35)
- Haematopoietic stem cell transplantation (HSCT) in severe autoimmune diseases: analysis of UK outcomes from the British Society of Blood and Marrow Transplantation (BSBMT) data registry 1997–2009 (2012) (34)
- Favorable outcomes with alemtuzumab-conditioned unrelated donor stem cell transplantation in adults with high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in first complete remission (2009) (34)
- The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia (2020) (33)
- E14a2 BCR-ABL1 transcript is associated with a higher rate of treatment-free remission in individuals with chronic myeloid leukemia after stopping tyrosine kinase inhibitor therapy (2017) (33)
- EVI-1 oncogene expression predicts survival in chronic-phase CML patients resistant to imatinib treated with second-generation tyrosine kinase inhibitors. (2010) (33)
- IL2-PE664Glu, a new chimeric protein cytotoxic to human-activated T lymphocytes. (1990) (33)
- ENESTnd 5-year (y) update: Long-term outcomes of patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) treated with frontline nilotinib (NIL) versus imatinib (IM). (2014) (32)
- Onset and outcome of pregnancy after autologous haematopoietic SCT (AHSCT) for autoimmune diseases: a retrospective study of the EBMT autoimmune diseases working party (ADWP) (2015) (32)
- A comparative assessment of the curative potential of reduced intensity allografts in acute myeloid leukaemia (2014) (31)
- Plerixafor is superior to conventional chemotherapy for first-line stem cell mobilisation, and is effective even in heavily pretreated patients (2014) (28)
- Spirit 2: An NCRI Randomised Study Comparing Dasatinib with Imatinib in Patients with Newly Diagnosed CML (2014) (28)
- A comparison of clofarabine with ara-C, each in combination with daunorubicin as induction treatment in older patients with acute myeloid leukaemia (2016) (26)
- Long-Term Outcomes in Patients with Chronic Myeloid Leukemia in Chronic Phase Receiving Frontline Nilotinib Versus Imatinib: Enestnd 10-Year Analysis (2019) (25)
- Pharmacologic markers and predictors of responses to imatinib therapy in patients with chronic myeloid leukemia (2008) (24)
- Naturally occurring CD4+ CD25+ FOXP3+ T-regulatory cells are increased in chronic myeloid leukemia patients not in complete cytogenetic remission and can be immunosuppressive. (2010) (23)
- A randomized study (WOS MM1) comparing the oral regime Z‐Dex (idarubicin and dexamethasone) with vincristine, adriamycin and dexamethasone as induction therapy for newly diagnosed patients with multiple myeloma (2004) (22)
- Oligodeoxynucleotide 5mers containing a 5'-CpG induce apoptosis through a mitochondrial mechanism in T lymphocytic leukaemia cells. (2000) (22)
- BCR-ABL Fusion Peptides and Cytotoxic T Cells in Chronic Myeloid Leukaemia (2001) (22)
- Bosutinib (BOS) Versus Imatinib for Newly Diagnosed Chronic Phase (CP) Chronic Myeloid Leukemia (CML): Final 5-Year Results from the Bfore Trial (2020) (21)
- Tyrosine Kinase Inhibitor Therapy Discontinuation for Patients with Chronic Myeloid Leukaemia in Clinical Practice (2019) (20)
- Prognosis of patients with chronic myeloid leukemia presenting in advanced phase is defined mainly by blast count, but also by age, chromosomal aberrations and hemoglobin (2019) (18)
- The clinical significance of ABCC3 as an imatinib transporter in chronic myeloid leukaemia (2014) (18)
- Peroxisome proliferator-activated receptor activation increases imatinib uptake and killing of chronic myeloid leukemia cells. (2012) (18)
- Chronic Lymphocytic Leukaemia Developing in the Course of Chronic Myeloid Leukaemia (2002) (18)
- Second-generation tyrosine kinase inhibitors improve the survival of patients with chronic myeloid leukemia in whom imatinib therapy has failed (2011) (17)
- FLAG-IDA and Ponatinib in Patients with Blast Phase Chronic Myeloid Leukaemia: Results from the Phase I/II UK Trials Acceleration Programme Matchpoint Trial (2019) (17)
- Use of yttrium-90-labeled anti-Tac antibody in primate xenograft transplantation. (1990) (17)
- BCR‐ABL1 tyrosine kinase activity at diagnosis, as determined via the pCrkL/CrkL ratio, is predictive of clinical outcome in chronic myeloid leukaemia (2010) (16)
- Tumour antigen-targeted immunotherapy for chronic myeloid leukaemia: is it still viable? (2009) (16)
- PTCH1 expression at diagnosis predicts imatinib failure in chronic myeloid leukaemia patients in chronic phase (2015) (15)
- Low leukotriene B4 receptor 1 leads to ALOX5 downregulation at diagnosis of chronic myeloid leukemia (2014) (15)
- Additional chromosomal abnormalities at chronic myeloid leukemia diagnosis predict an increased risk of progression. (2021) (15)
- c-Myc inhibition decreases CIP2A and reduces BCR-ABL1 tyrosine kinase activity in chronic myeloid leukemia (2015) (15)
- Defining the Optimal Total Number of Chemotherapy Courses in Younger Patients With Acute Myeloid Leukemia: A Comparison of Three Versus Four Courses (2020) (14)
- Poor cellular uptake of antisense oligodeoxynucleotides: an obstacle to their use in chronic myeloid leukaemia. (1995) (14)
- Real‐world tyrosine kinase inhibitor treatment pathways, monitoring patterns and responses in patients with chronic myeloid leukaemia in the United Kingdom: the UK TARGET CML study (2020) (14)
- Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial (2022) (14)
- Dual Glutathione‐S‐Transferase‐θ1 and ‐μ1 Gene Deletions Determine Imatinib Failure in Chronic Myeloid Leukemia (2014) (14)
- Molecular monitoring during dose reduction predicts recurrence after TKI cessation in CML (2020) (13)
- Evaluating the use of plerixafor in stem cell mobilisation – an economic analysis of the PHANTASTIC trial (2016) (13)
- Heterogeneous leukemia stem cells in myeloid blast phase chronic myeloid leukemia. (2016) (13)
- CIP2A- and SETBP1-mediated PP2A inhibition reveals AKT S473 phosphorylation to be a new biomarker in AML. (2018) (13)
- A population study showing that the advent of second generation tyrosine kinase inhibitors has improved progression-free survival in chronic myeloid leukaemia. (2013) (12)
- BCR-ABL peptide vaccination in healthy subjects: immunological responses are equivalent to those in chronic myeloid leukaemia patients. (2011) (12)
- Serine 162, an Essential Residue for the Mitochondrial Localization, Stability and Anti-Apoptotic Function of Mcl-1 (2012) (12)
- The influence of class II HLA type on the lymphoproliferative response of normal donors to a bcr-abl fusion peptide. (1996) (12)
- Nilotinib Shows Safety and Efficacy in Older Patients (≥ 65 years) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase Comparable with That in Younger Patients with Chronic Myeloid Leukemia in Chronic Phase: Results From ENESTnd, (2011) (11)
- Addition of the mammalian target of rapamycin inhibitor, everolimus, to consolidation therapy in acute myeloid leukemia: experience from the UK NCRI AML17 trial (2018) (11)
- Nilotinib-induced metabolic dysfunction: insights from a translational study using in vitro adipocyte models and patient cohorts (2019) (11)
- Ponatinib with fludarabine, cytarabine, idarubicin, and granulocyte colony-stimulating factor chemotherapy for patients with blast-phase chronic myeloid leukaemia (MATCHPOINT): a single-arm, multicentre, phase 1/2 trial. (2021) (11)
- Dasatinib may overcome the negative prognostic impact of KIR2DS1 in newly diagnosed patients with chronic myeloid leukemia. (2012) (11)
- CpG oligodeoxynucleotide 5mer-induced apoptosis in MOLT-4 leukaemia cells does not require caspase 3 or new protein synthesis. (2003) (11)
- BCR-ABL-specific T cells can be detected in healthy donors and in chronic myeloid leukemia patients following allogeneic stem cell transplantation. (2004) (11)
- Reasons For Survival Improvement In Core Binding Factor AML: A 25 Year Analysis Of The UK MRC/NCRI AML Trials (2013) (11)
- Management of chronic myeloid leukaemia in relapse following donor lymphocyte infusion induced remission: a retrospective study of the clinical trials committee of the British Society of Blood & Marrow Transplantation (BSBMT) (2005) (11)
- Cardiac allograft survival across major histocompatibility complex barriers in the rhesus monkey following T lymphocyte-depleted autologous marrow transplantation. II. Prolonged allograft survival with extensive marrow T cell depletion. (1989) (10)
- Delayed commencement of granulocyte colony-stimulating factor following autologous bone marrow transplantation accelerates neutrophil recovery and is cost-effective. (1994) (10)
- Plerixafor is cost‐effective compared to conventional chemotherapy for first‐line haematopoietic stem cell mobilization: Data from the PHANTASTIC trial (2015) (10)
- Preliminary Results from a Phase 2 Trial of AG-858, an Autologous Heat Shock Protein-Peptide Vaccine, in Combination with Imatinib in Patients with Chronic Phase Chronic Myeloid Leukemia (CML) Resistant to Prior Imatinib Monotherapy. (2005) (9)
- A Randomised Comparison of the Sequential Addition of the FLT3 Inhibitor Lestaurtinib (CEP701) to Standard First Line Chemotherapy for FLT3-Mutated Acute Myeloid Leukemia: The UK Experience (2014) (9)
- Discovery of a Novel CIP2A Variant (NOCIVA) with Clinical Relevance in Predicting TKI Resistance in Myeloid Leukemias (2021) (9)
- Prostaglandin E2 inhibits in vitro and in vivo lymphocyte responses in allogeneic transplantation. (1990) (9)
- The outcome of sibling and unrelated donor allogeneic stem cell transplantation in adult patients with acute myeloid leukemia in first remission who were initially refractory to first induction chemotherapy. (2006) (9)
- CMV~IMPACT: Results of a Randomized Controlled Trial of Immuno-Prophylactic Adoptive Cellular Therapy following Sibling Donor Allogeneic HSCT (2014) (8)
- Assessment of BCR-ABL1 Transcript Levels At 3 Months Is the Only Requirement for Predicting Outcome for Patients with Chronic Myeloid Leukemia Treated with Imatinib (2011) (8)
- Introducing a Predictive Score for Successful Treatment Free Remission in Chronic Myeloid Leukemia (CML). (2019) (8)
- The Predictive Value of Early Molecular Response in Chronic Phase CML Patients Treated with Dasatinib First Line Therapy (2011) (8)
- Chronic Myeloid Leukaemia Patients with Stable Molecular Responses (at least MR3) May Safely Decrease the Dose of Their Tyrosine Kinase Inhibitor: Data from the British Destiny Study (2016) (8)
- Facts and uncertainties in monitoring treatment response in chronic myeloid leukaemia. (2009) (8)
- Outcomes of older patients aged 60 to 70 years undergoing reduced intensity transplant for acute myeloblastic leukemia: results of the NCRI acute myeloid leukemia 16 trial (2021) (8)
- Nilotinib concentration in Cell Lines and CML CD34+ Cells Is Not Mediated by Active Uptake or Efflux by Major Drug Transporters (2008) (7)
- Spirit 2: Final 5 Year Analysis of the UK National Cancer Research Institute Randomized Study Comparing Imatinib with Dasatinib in Patients with Newly Diagnosed Chronic Phase CML (2018) (7)
- Rapid diagnosis of chronic myeloid leukemia by flow cytometric detection of BCR-ABL1 protein (2011) (7)
- Randomized evaluation of quizartinib and low-dose ara-C vs low-dose ara-C in older acute myeloid leukemia patients (2021) (7)
- Expression of c-myc is not critical for cell proliferation in established human leukemia lines (2001) (7)
- The effect on lymphocyte subsets of decreasing/stopping tyrosine kinase inhibitor therapy in chronic myeloid leukaemia: data from the DESTINY trial (2018) (7)
- Assessment of Quality of Life in the NCRI Spirit 2 Study Comparing Imatinib with Dasatinib in Patients with Newly-Diagnosed Chronic Phase Chronic Myeloid Leukaemia (2015) (7)
- Initial reduction of therapy prior to complete treatment discontinuation in chronic myeloid leukaemia: final results of the British DESTINY Study (2019) (6)
- The Eutos Population-Based Registry : Evaluation of Baseline Characteristics and First Treatment Choices Of 2983 Newly Diagnosed Chronic Myeloid Leukemia (Cml) Patients from 20 European Countries (2014) (6)
- Bone Turnover Following Autologous Transplantation in Multiple Myeloma (2002) (5)
- Response To Ruxolitinib In Patients With Intermediate-1, Intermediate-2 and High-Risk Myelofibrosis: Interim Results Of The UK Robust Trial (2013) (5)
- SPIRIT 2: an NCRI randomised study comparing dasatinib with imatinib in patients with newly diagnosed chronic myeloid leukaemia-2 year follow up (2015) (5)
- Diagnostic Criteria for Hematopoietic Stem Cell Transplantation-Associated Microangiopathy (TAM): Results of a Consensus Process by an International Working Group. (2005) (5)
- Characterisation of Nilotinib Transport in Chronic Myeloid Leukaemia Cells. (2007) (4)
- Molecular dynamics during reduction of TKI dose reliably identify molecular recurrence after treatment cessation in CML. (2020) (4)
- Molecular monitoring of complete cytogenetic responders following treatment with imatinib (STI571, Gleevec) for CML: A report from the UKSTI571 study group. (2002) (4)
- A Comparison of Single Dose Gemtuzumab Ozogamicin 3mg/m2 and 6mg/m2 Combined with Induction Chemotherapy in Younger Patients with AML: Data from the UK NCRI AML17 Trial (2014) (4)
- APL of all risk groups is highly curable with a chemo-free combination of attenuated arsenic trioxide and atra (2015) (4)
- A randomised evaluation of low‐dose cytosine arabinoside (ara‐C) plus tosedostat versus low‐dose ara‐C in older patients with acute myeloid leukaemia: results of the LI‐1 trial (2021) (4)
- Cancerous Inhibitor of Protein Phosphatase 2A (CIP2A) modifies energy metabolism via 5' AMP-activated protein kinase signalling in malignant cells. (2019) (4)
- CD34 Positive Selection as Prophylaxis Against Graft Versus Host Disease in Allogeneic Peripheral Blood Stem Cell Transplantation (2003) (4)
- Human plasma causes rapid dysfunction in ex vivo pig hearts. (1994) (4)
- CML Patients In Clinical Trials Represent Fairly Well The General Population Of CML Patients: A Comparative Analysis Of 5803 Patients From The EUTOS Registry (2013) (3)
- Validation of CIP2A as a Biomarker of Subsequent Disease Progression and Treatment Failure in Chronic Myeloid Leukaemia (2021) (3)
- Dose Interruption/Reduction Of Tyrosine Kinase Inhibitors In The First 3 Months Of Treatment of CML Is Associated With Inferior Early Molecular Responses and Predicts For An Increased Likelihood Of Discontinuation Of The 1st Line Agent (2013) (3)
- Identification of a good c-myc antisense oligodeoxynucleotide target site and the inactivity at this site of novel NCH triplet--targeting ribozymes. (1999) (3)
- Soluble HLA/peptide monomers cross-linked with co-stimulatory antibodies onto a streptavidin core molecule efficiently stimulate antigen-specific T cell responses (2009) (3)
- An Operational Definition of Primary Refractory Acute Myeloid Leukaemia Which Allows Early Identification of Patients for Whom Allogeneic Stem Cell Transplantation Represents the Only Curative Therapy (2015) (3)
- Placental Growth Factor: a Novel, Stromal-Derived Target in Human CML. (2009) (3)
- Evidence that a BCR-ABL fusion peptide does not induce lymphocyte proliferation or cytokine production in vitro. (2007) (3)
- Long-term bone marrow cultures established from bone marrow transplant recipients. (1993) (3)
- Incidence of CML in Europe -- a Comparison of 19 European Countries with US SEER Data (2014) (3)
- Unlike Imatinib, Dasatinib Uptake into Chronic Myeloid Leukaemia Cells Is Independent of hOCT1 Expression. (2007) (3)
- Bone-marrow donation by mentally incapable adults (1998) (3)
- Practical implementation of an adaptive phase I/II design in chronic myeloid leukaemia: evaluating both efficacy and toxicity using the EffTox design (2013) (3)
- resistance Active transport of imatinib into and out of cells: implications for drug (2013) (2)
- Baseline Characteristics of CML Patients Accross Europe - Comparing Real-World Patients with Patient Collectives Included in Clinical Trials (2014) (2)
- The influence of target protein half-life on the effectiveness of antisense oligonucleotides (1998) (2)
- Correction to: Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis (2021) (2)
- CIP 2 Aand SETBP 1-mediated PP 2 A inhibition reveals AKT S 473 phosphorylation to be a new biomarker in AML (2018) (2)
- Correction: CD93 is expressed on chronic myeloid leukemia stem cells and identifies a quiescent population which persists after tyrosine kinase inhibitor therapy (2020) (2)
- Selection and management of older patients with acute myeloid leukemia treated with glasdegib plus low-dose cytarabine: expert panel review (2020) (2)
- Real-Time Detection of PML-RARA and RARA-PML Fusion Transcripts in High Risk Acute Promyelocytic Leukemia (APL) Treated with Arsenic Trioxide (ATO): Implications for Realization of Pre-Emptive Therapy for Molecular Relapse. (2006) (2)
- Immunotherapeutic strategies in chronic myeloid leukemia (2007) (2)
- PTCH1 Expression At Diagnosis Reliably Predicts Treatment Failure in Imatinib-Treated Chronic Myeloid Leukaemia Patients (2012) (1)
- Population pharmacokinetic (PK) and exposure-response analysis of nilotinib in newly diagnosed Ph+ chronic myeloid leukemia in chronic phase: Results from ENESTnd. (2010) (1)
- in younger patients with acute myeloid leukemia ozogamicin with intensive chemotherapy in induction and consolidation A feasibility study of simultaneous administration of gemtuzumab (2013) (1)
- Cardiac, vascular, and hypertension safety of bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia in the BFORE trial. (2019) (1)
- Another set of guidelines for chronic myeloid leukaemia (2020) (1)
- Axl Represents a Therapeutic Target In T315I-Mutated and WT Chronic Myeloid Leukemia (2013) (1)
- Transplantation of antisense oligonucleotide (ODN) purged autografts in chronic myeloid leukaemia (CML) (1997) (1)
- Characterisation of HLA-A3 restricted peptide from the BCR-ABL fusion protein of the Philadelphia chromosome using nano-electrospray ion trap mass spectrometry (2001) (1)
- Loss or Inhibition of Stromal-Derived PlGF Prolongs Survival of Mice with Imatinib-Resistant Bcr-Abl1+ Leukemia. (2020) (1)
- The Eutos Population Based Registry - Incidences of CML Across Europe (2014) (1)
- EUROPEAN SUB-REGISTRY OF CHRONIC MYELOID LEUKEMIA (CML) PATIENTS (PTS) IN FAILURE AFTER IMATINIB THERAPY (IFP): RATIONALE, STUDY DESIGN AND CURRENT STATUS. A STUDY FROM THE EUROPEAN LEUKEMIANET (ELN) (2010) (1)
- T-Cell Depleted Unrelated Donor Stem Cell Transplants Appear to Be of Value for Adult Philadelphia Chromosome Negative ALL Patients and Should Be Evaluated Prospectively in New Large Group Studies (2008) (1)
- TRANSCRIPT LEVELS OF THE HEDGEHOG PATHWAY MEMBERS PTCH1 AND SMO ARE PREDICTIVE OF IMATINIB FAILURE IN PRE-TREATMENT CHRONIC MYELOID LEUKAEMIA (2014) (1)
- EFFECT OF CHIMERIC AND CONVENTIONALLY LINKED ANTISENSE OLIGONUCLEOTIDES ON BCR-ABL EXPRESSION IN INTACT CHRONIC MYELOID-LEUKEMIA CELLS (1995) (1)
- Direct evidence that chronic myeloid leukaemia (CML) cells can express BCR-ABL junctional oligopeptides in association with class IHLA (2000) (1)
- PS1167 INDIVIDUAL RESPONSE OF CML PATIENTS TO TKI DOSE REDUCTION CAN RELIABLY IDENTIFY PATIENTS WITH HIGH RISK OF MOLECULAR RELAPSE AFTER TREATMENT CESSATION (2019) (1)
- ANALYSIS OF TREATMENT AND OUTCOME DATA OF 2904 PATIENTS FROM THE EUTOS POPULATION-BASED REGISTRY (2015) (1)
- Stem cell transplantation (1997) (1)
- fit for intensive chemotherapy treatment for older patients with acute myeloid leukemia not considered A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line (2013) (1)
- T cell function in chronic myeloid leukemia and its treatment with tyrosine kinase inhibitors--clues from and for sarcoidosis. (2009) (1)
- Response to imatinib mesylate in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukaemia (2003) (1)
- Fertility recovery and pregnancy after autologous hematopoietic stem cell transplantation for autoimmune diseases: a retrospective study of the EBMT Autoimmune Diseases Working Party (2014) (1)
- Leukemia Stem Cell Potential of Different Progenitor Subpopulations in Myeloid Blast Phase CML (2014) (1)
- A Randomised Assessment of Vosaroxin Monotherapy and Vosaroxin Combined with Low Dose Ara-C Versus Low Dose Ara-C in Older Patients with Acute Myeloid Leukaemia (2014) (1)
- BGB324 Represents an Axl and BCR-ABL1 Inhibitor with Activity in the T315I Mutant (2014) (1)
- Treatment and Outcome Analysis of 2,904 Pateints from the EUTOS Population Based Registry (2015) (1)
- Safety considerations of a new anti-CMV cellular therapy - experience from donor-derived, directly selected, adoptively transferred T cells (Cytovir (TM) CMV) in 2 randomized clinical trials (2015) (0)
- Treatment and outcome of 2904 CML patients from the EUTOSpopulation-based registry (2017) (0)
- Outcome Of Pregnancy After Autologous Hematopoietic Stem Cell Transplantation (AHSCT) For Autoimmune Diseases (AD): A Retrospective Study Of The EBMT Autoimmune Diseases Working Party (ADWP) (2013) (0)
- Early identification of Patients with Primary Refractory Acute Myeloid Leukaemia who Benefit from Allogeneic stem cell transplantation: an analysis of 8,907 patients from the uk ncrn aml working group (2016) (0)
- Use of quantitative PCR approaches to predict relapse and direct molecularly targeted therapy with arsenic trioxide (ATO) in acute promyelocytic leukaemia (APL)[Abstract] (2007) (0)
- The small molecule axl inhibitor BGB324 shows activity against T315I-mutated and BCR-ABL1 wt chronic myeloid leukemia (2014) (0)
- Loss or inhibition of stroma-derived PLGF prolongs survival of imatinib-resistant BCR-ABL+ leukaemia (2011) (0)
- Cardiac, Vascular and Hypertension Safety of Bosutinib vs Imatinib for Newly Diagnosed Chronic Myeloid Leukemia in the BFORE Trial (2019) (0)
- KIR2DS1 Genotype Predicts for Cytogenetic Response, Progression-Free Survival and Overall Survival In Patients with Chronic Phase CML on Imatinib (2010) (0)
- PTCH1 expression at diagnosis of chronic myeloid leukaemia reliably predicts treatment failure for patients on imatinib (2014) (0)
- Targets for clinical peptide vaccination strategies in chronic myeloid leukemia (2007) (0)
- Discovery of NOvel CIP2A VAriant (NOCIVA) and its clinical relevance in myeloid leukemias (2020) (0)
- chemotherapy and autografting in multiple myeloma Biochemical markers of bone turnover following high-dose (2013) (0)
- PP2A Inhibition By CIP2A or SETBP1 Leads to Elevated Levels of AKT S473 Which Can be Used As a Biomarker of Outcome in Acute Myeloid Leukaemia (2015) (0)
- Serotonin re-uptake transporter gene polymorphisms are associated with imatinib-induced diarrhoea in chronic myeloid leukaemia patients (2020) (0)
- DNA-Based Digital PCR for the Quantification of Residual Disease in CML — Sensitivity or Specificity? (2018) (0)
- The European Treatment and Outcome Study (EUTOS) for Chronic Myeloid Leukemia (CML). A Prospective, Population-Based European Registry. (2009) (0)
- A randomised comparison of FLAG‐Ida versus daunorubicin combined with clofarabine in relapsed or refractory acute myeloid leukaemia: Results from the UK NCRI AML17 trial (2022) (0)
- Autologous stem cell transplantation for progressive multiple sclerosis: an update of the EBMT autoimmune diseases working party database. (2006) (0)
- e19a2 positive chronic myeloid leukaemia with an interstitial deletion of BCR exon e16 (2002) (0)
- Efficacy and Safety of First-Line Bosutinib versus Imatinib in the BFORE trial : 18-Month Follow-up (2018) (0)
- PS1182 REAL WORLD TYROSINE KINASE INHIBITOR TREATMENT PATHWAYS, MONITORING PATTERNS AND RESPONSES COMPARED WITH ELN RECOMMENDATIONS IN CHRONIC MYELOID LEUKAEMIA: FINAL ANALYSIS OF THE UK TARGET CML STUDY (2019) (0)
- The hOCT1 single nucleotide polymorphisms M420del and M408V alter imatinib uptake and modify clinical outcome in imatinib treated chronic myeloid leukaemia (2013) (0)
- A NATIONAL EXPERIENCE OF THE USE OF PONATINIB IN PATIENTS MULTIPLE TYROSINE KINASE INHIBITORS CONFIRMS EFFICACY IN A HEAVILY PRE-TREATED COHORT OF PATIENTS WITH PH plus LEUKAEMIAS (2014) (0)
- CLONAL STRUCTURES OF LEUKAEMIA STEM CELL POPULATIONS IN MYELOID BLAST PHASE CHRONIC MYELOID LEUKAEMIA (2016) (0)
- A Genome-wide screen identifies novel frequently methylated genes in leukemia and genes associated with clinical outcome in chronic myeloid leukaemia (2010) (0)
- A Novel Splice Site Variant of hOCT-1 and Response to Imatinib. (2012) (0)
- Optimising the use of arsenic trioxide in 'high risk' acute promyelocytic leukaemia (APL): The UK experience. (2005) (0)
- BGB324 Inhibits BCR-ABL TKI-Resistant Chronic Myeloid Leukemia (2015) (0)
- BOOK REVIEW: CAMBRIDGE MEDICAL REVIEWS: HAEMATOLOGICAL ONCOLOGY. Vol. 4. Armitage, Newland, Keating, Burnett (Eds). Cambridge University Press. 1995. £55.00 (hardback). ISBN: 0 521 46169 3. (1996) (0)
- chronic myeloid leukemia: 2013 European LeukemiaNet recommendations for the management of (2013) (0)
- Improving the molecular efficacy of antisense oligonucleotides (ODN) in chronic myeloid leukaemia (1997) (0)
- Analysis of BCR ABL1 Tyrosine Kinase Domain Mutations In Primitive Chronic Myeloid Leukemia Cells Identifies a Unique Mutator Phenotype (2010) (0)
- Allogeneic Stem Cell Transplantation Induces Long Term Survival in Pateitns with Advanced Chronic Myeloid Leukaemia:A Study of the British Society for Blood and Marrow Transplantation, (2011) (0)
- P713: REAL-WORLD MANAGEMENT OF PATIENTS WITH CHRONIC MYELOID LEUKAEMIA (CML): FIRST ANALYSIS FROM THE UK NATIONAL REGISTRY FOR CML (2022) (0)
- C-MYC antisense morpholino oligonucleotide analogue induces mis-splicing of mRNA in living cells (1998) (0)
- Antisense oligonucleotides targeting BCR-ABL for purging autografts in chronic myeloid leukaemia (1998) (0)
- Psychosocial morbidity following bone marrow transplantation is related to previous experience of intensive therapy (1995) (0)
- c-myc antisense morpholino 28-mer induces missplicing of mRNA in living cells (1999) (0)
- Dual PI3K/mTOR inhibition in combination with inhibition of autophagy to improve treatment response for BCR-ABL independent mechanisms of TKI-resistance in CML (2015) (0)
- Evaluation of prospective real-time quantitative PCR monitoring for minimal residual disease to predict relapse and direct molecularly targeted therapy with arsenic trioxide in acute promyelocytic leukaemia: analysis of 407 patients, including results of the MRC AML15 trial [Abstract] (2008) (0)
- PF413 CARDIAC, VASCULAR, AND HYPERTENSION SAFETY OF BOSUTINIB VS IMATINIB FOR NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA IN THE BFORE TRIAL (2019) (0)
- Clinical and Functional Evidence That Drug Transporter Expression Dictates the Response to Imatinib in Chronic Myeloid Leukaemia. (2006) (0)
- DE-ESCALATION OF TYROSINE KINASE INHIBITOR THERAPY IS SAFE IN CHRONIC MYELOID LEUKAEMIA IN DURABLE MOLECULAR RESPONSE (>= MR3 FOR >= 12 MONTHS): INITIAL RESULTS IN THE BRITISH DESTINY STUDY (2016) (0)
- The uptake of antisense oligonucleotide conjugates into chronic myeloid leukaemia cells (1996) (0)
- newly diagnosed patients with chronic myeloid leukemia in KIR2DS1 Dasatinib may overcome the negative prognostic impact of (2013) (0)
- CARDIAC ALLOGRAFT SURVIVAL ACROSS MAJOR HISTOCOMPATIBILITY COMPLEX BARRIERS IN THE RHESUS AUTOLOGOUS MARROW TRANSPLANTATION MONKEY FOLLOWING T LYMPHOCYTE‐DEPLETED (1989) (0)
- Clinical BCR-ABL Peptide Vaccination in Chronic Myeloid Leukaemia: Results of the EPIC Study. (2006) (0)
- Chronic Myeloid LeukemiaResearch Paper (2005) (0)
- The pCrKL/CrKL ratio at initial diagnosis is predictive of treatment outcome in chronic myeloid leukaemia (2010) (0)
- Comparison of streptolysin-O permeabilisation, electroporation and lipophilic conjugation for delivering antisense oligonucleotides targeting BCR-ABL (1998) (0)
- The UK SPIRIT 1 trial in newly-diagnosed chronic myeloid leukaemia (CML) (2022) (0)
- Final results of UK multi-centre, phase II study of Campath-1h dose de-escalation prior to non-myeloablative hla-identical sibling stem cell transplantation (2010) (0)
- Reply to Constance et al. (2017) (0)
- Naturally occurring CD4+ CD25+ FOXP3+ T regulatory cells are increased in chronic myeloid leukaemia patients with high BCR-ABL transcripts and can suppress anti-BCR-ABL responses (2010) (0)
- Bone marrow effects of anticancer therapy (1997) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Richard E Clark?
Richard E Clark is affiliated with the following schools:
